Cut stroke in half: Polypill for primary prevention in stroke

Michael Brainin, Valery Feigin, Sheila Martins, Karl Matz, Jayanta Roy, Peter Sandercock, Yvonne Teuschl, Jaakko Tuomilehto, Anita Wiseman

Research output: Journal article (peer-reviewed)Review article

27 Citations (Scopus)


This review summarizes the potential for polypill therapies for stroke prevention. While a number of studies applying different approaches regarding polypill have been performed, none of them has had a focus on stroke as the main outcome. A combination pill containing drugs such as statins, diuretics, and other antihypertensives is currently available in various formats. Estimates focusing mostly on primary prevention show that using such a combination drug a reduction in the 5-year stroke incidence by 50% can be achieved - especially in low- and middle-income countries with a high prevalence of risk factors even among people at young ages. A combination of a large supporting population-wide program with a registry-based quality control is the most likely perspective and can be achieved within a reasonable time frame and potentially have significant influence in young stroke populations.

Original languageEnglish
Pages (from-to)633-647
Number of pages15
JournalInternational Journal of Stroke
Issue number6
Publication statusPublished - 01 Aug 2018


  • Cardiovascular Agents/therapeutic use
  • Drug Combinations
  • Humans
  • Medication Adherence
  • Polypharmacy
  • Population Groups
  • Primary Prevention
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Stroke/drug therapy


Dive into the research topics of 'Cut stroke in half: Polypill for primary prevention in stroke'. Together they form a unique fingerprint.

Cite this